Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242632 · ClinicalTrials.gov registry record · NA
Treatment With Namenda in Women at Risk for Cognitive Decline
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT00242632: Completed NA study, sponsored by Stanford University.
NCT00242632 is a NA study that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242632, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Interventions
- DRUG Namenda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242632
The ClinicalTrials.gov registry entry for NCT00242632 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Namenda is the first listed.
NCT00242632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242632 about?
NCT00242632 is a clinical study titled "Treatment With Namenda in Women at Risk for Cognitive Decline". This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potenti...
What is the current status of trial NCT00242632?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2004-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00242632?
The interventions under investigation include: Namenda (DRUG).
Who is sponsoring clinical trial NCT00242632?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.